You should not change your dosing regimen or stop taking Wegovy (semaglutide) as prescribed without discussing with your provider first
It enhances insulin secretion from the pancreas, inhibits glucagon release (which prevents the liver from producing excess glucose), and slows gastric emptying, contributing to prolonged satiety
Approval (2017) FDA News Release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA News Release (August 15th, 2025): FDA Approves Treatment for Serious Liver Disease Known as MASH OZEMPIC (semaglutide) injection, for subcutaneous use
Jessica Drummond 00:15:27 And I think this is why people like pelvic TS and OTS and nutritionists and dietitians need to really understand these medications, because, you know, we might be seeing as a pelvic floor For rehab therapists like hemorrhoids or constipation or real like pushing and bad ass energetic organization, between kind of holding the breath and pushing because theyre more and more and more constipated
Gross CJ, Henderson LM, Savaiano DA